Ind-Swift Laboratories Limited (INDSWFTLAB) fundamentals
Ind-Swift Laboratories Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as INDSWFTLAB (ISIN INE915B01019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Ind-Swift Laboratories Limited does
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Valuation and market data
| Last close | ₹338.80 |
|---|---|
| Market capitalisation | ₹2,825 crore |
| Enterprise value | ₹2,428 crore |
| P/E (TTM) | 65.66 |
| Price to book | 2.04 |
| Price to sales (TTM) | 2.36 |
| Book value per share | ₹165.96 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jul 02 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹696 crore | ₹51 crore | ₹43 crore | 5.16 |
| Mar 2025 | ₹643 crore | ₹258 crore | ₹251 crore | 37.24 |
| Mar 2024 | ₹1,326 crore | ₹582 crore | ₹421 crore | 71.24 |
| Mar 2023 | ₹1,241 crore | ₹87 crore | ₹48 crore | 8.10 |
| Mar 2022 | ₹1,082 crore | ₹13 crore | ₹-2 crore | -0.36 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 42.9% |
|---|---|
| Foreign institutions (FII) | 10.8% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.2% |
| Retail and others | 46.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.